05:00 PM EDT, 09/27/2024 (MT Newswires) -- GE HealthCare Technologies ( GEHC ) said Friday that the US Food and Drug Administration approved Flyrcado, or flurpiridaz F 18, injection for the detection of coronary artery disease.

The company said it acquired exclusive rights to commercialize flurpiridaz F 18 globally from Lantheus in 2017 and expects Flyrcado to be available in the US markets in early 2025.

Flyrcado can be manufactured in an offsite pharmacy and will be available as a ready-to-use unit dose with a half-life of 109 minutes, GE HealthCare ( GEHC ) added.